GRFS.O

Grifols maintains a capital structure with a debt-to-equity ratio of 1.83, indicating a relatively high leverage position compared to industry norms. The company's liquidity is assessed as medium, with a current ratio of 2.51, suggesting it can cover short-term obligations but with limited cash reserves. Free cash flow stands at 399 million EUR, which is a positive sign for operational efficiency, though the company's cash and equivalents are only 8 million EUR, indicating a potential liquidity constraint. In terms of profitability, Grifols reports a return on equity (ROE) of 7.63% and a return on assets (ROA) of 2.04%. These figures are below the industry median for ROE and ROA, suggesting that the company is not generating returns as efficiently as its peers. The price-to-earnings (P/E) ratio of 5.35 is significantly lower than the industry median, indicating that the stock may be undervalued relative to its earnings. Grifols' revenue is primarily concentrated in its core pharmaceuticals business, with no significant diversification across segments. The company's geographic exposure is not disclosed in the available data, but its operations are likely global given its classification and industry presence. The lack of segmental or geographic diversification could pose a concentration risk if demand in its primary markets declines. The company's growth trajectory is modest, with no specific revenue growth projections provided in the available data. Analysts have assigned a mean price target of 12.20 EUR, which is 46.4% higher than the current market price of 8.33 EUR. This suggests a positive outlook, though the company's capital expenditure of -423 million EUR indicates a reduction in investment, which may limit future growth potential. Risk factors for Grifols include its high debt load and limited liquidity. The company's net cash position is negative after subtracting total debt, which could constrain its ability to invest in growth or weather economic downturns. The risk of dilution is assessed as low, with no significant dilution potential reported in the data. However, the company's reliance on debt financing could increase its financial risk in the event of rising interest rates. Recent events for Grifols include the publication of its latest financial results, which show a revenue of 7.524 billion EUR and a net income of 402 million EUR. Analysts have issued a mixed set of recommendations, with a mean recommendation of 2.50 (a "hold" rating), and a median price target of 12.20 EUR. These signals suggest a cautious but generally positive outlook for the company.